In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma - The Lancet www.thelancet.com/journals/lan...
Chimeric antigen receptor (CAR) T-cell therapy has shown impressive efficacy in treating
relapsed or refractory multiple myeloma. Nonetheless, its availability is substantially
restricted by complex m...